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ABSTRACT Chronic hypersensitivity pneumonitis is a common fibrotic interstitial lung disease. The
prevalence of pulmonary hypertension diagnosed by right heart catheterisation and its cardiopulmonary
function findings in patients with chronic hypersensitivity pneumonitis are unknown.
Consecutive symptomatic patients with chronic hypersensitivity pneumonitis were prospectively
evaluated. All patients were submitted to right heart catheterisation, pulmonary function testing, a
6-min walk test, echocardiography, blood gas determination and N-terminal pro-brain natriuretic peptide
analyses. Nonhypoxaemic patients also underwent incremental cardiopulmonary exercise testing.
50 patients underwent right heart catheterisation; 25 (50%) of these had pulmonary hypertension and 22
(44%) had a pre-capillary haemodynamic pattern. The patients with pre-capillary pulmonary hypertension
had lower forced vital capacity (mean¡SD 50¡17% versus 69¡22% predicted, p,0.01), carbon monoxide
diffusing capacity (37¡12% versus 47¡14% predicted, p,0.01), arterial oxygen tension (median
(interquartile range) 59.0 (47.8–69.3) versus 73.0 (62.2–78.5) mmHg, p,0.01) and saturation after the
6-min walk test (78¡8% versus 86¡7%, p,0.01). In pre-capillary pulmonary hypertension, oxygen uptake
was also lower at the anaerobic threshold (41¡11% versus 50¡8% predicted, p50.04) and at peak exercise
(12.8¡1.6 versus 15.0¡2.5 mL?kg-1?min-1, p50.02).
Pre-capillary pulmonary hypertension is common in symptomatic chronic hypersensitivity pneumonitis
and is related to interstitial lung disease severity. Additionally, pulmonary hypertension is more prevalent in
hypoxaemic patients with impaired lung function and exercise capacity.
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Introduction
Interstitial lung diseases (ILDs) are common causes of pre-capillary pulmonary hypertension (PH) and are
classified into group III of the international aetiological classification of PH [1, 2]. Pre-capillary PH is
defined by mean pulmonary arterial pressure (mPAP) o25 mmHg and pulmonary arterial wedge pressure
(PAWP) f15 mmHg on right heart catheterisation (RHC) [2]. When present in patients with ILD, pre-
capillary PH is associated with a significantly poorer prognosis [3–6].
The prevalence of PH varies widely among the different forms of ILD, depending on the diagnostic
algorithm, the PH definition used and the severity of the underlying parenchymal impairment [7].
Haemodynamic data are mainly available from patients in lung transplantation programmes, in whom a
high prevalence of PH is likely because of their ILD severity. In an outpatient setting, echocardiography is
frequently used to identify PH. However, this method is commonly inaccurate and can lead to considerable
misdiagnosis [8, 9], particularly among group III patients [10, 11].
Among patients with ILD, hypersensitivity pneumonitis (HP) is a common condition [12]. HP is a
pulmonary disease caused by the inhalation of one of various antigens that trigger a diffuse inflammatory
response in the small airways and pulmonary parenchyma in susceptible individuals [13]. The causative
antigens include bacteria, fungi, protozoa, low-molecular-weight chemical compounds, and animal and
insect proteins present in different environments [14]. The spectrum of clinical presentation may vary with
the frequency and intensity of antigen exposure and the host immune response [13]. HP can develop into a
chronic disease, leading to irreversible lung fibrosis, which characterises chronic HP.
With the exception of two case-series studies [15, 16] and one retrospective study based on
echocardiographic diagnosis [17], the literature on PH in chronic HP is scarce. In particular, there are
no published data concerning the prevalence of invasively diagnosed PH in patients with chronic HP.
Therefore, we sought to determine the prevalence of PH at RHC in symptomatic patients with chronic HP,
and to compare cardiopulmonary function findings between cases with and without PH.
Material and methods
Study design and patients
This prospective, cross-sectional study was performed between August 2011 and February 2013 at the ILD
Outpatient Clinic of the Federal University of Sa˜o Paulo, Brazil. We evaluated 1023 consecutive outpatients
with ILD who came for a routine consultation during this period. All symptomatic patients from
18–80 years of age with chronic HP were recruited for a standardised PH assessment. Patients with
comorbidities that could lead to PH were excluded (fig. 1). All patients provided written informed consent,
and the study protocol was approved by the Institutional Medical Ethics Committee.
Symptomatic patients were defined as patients with a baseline dyspnoea index ,9 points at the time of
evaluation [18] and stable disease, characterised by the absence of exacerbations and no change in baseline
therapy during the 30 days before study enrolment.
Patients with chronic HP were defined as patients with relevant exposure preceding respiratory symptoms
[19] and fibrotic disease visible on high-resolution computed tomography (HRCT) scans of the lungs,
without another identifiable cause of ILD, in addition to at least one of the following findings.
1) Improvement of symptoms upon the withdrawal of exposure or clinical/functional deterioration upon
re-exposure [20]. 2) At least two of the following HRCT-consistent HP findings: bilateral ground-glass
opacity, poorly defined centrilobular nodules and mosaic patterns [21]. 3) A classic histological triad
characterised by chronic interstitial pneumonia with peribronchiolar accentuation, bronchiolitis and
non-necrotising granulomas or giant cells [22]. 4) Other consistent histological findings, including
bronchiolocentric interstitial pneumonia, nonspecific interstitial pneumonia (NSIP) or usual interstitial
pneumonia (UIP)-like findings [22].
Measurements
All patients were submitted to RHC, pulmonary function testing (PFT), a 6-min walk test (6MWT),
echocardiography, blood gas analysis and serum N-terminal pro-brain natriuretic peptide level
determination. Nonhypoxaemic patients (arterial oxygen saturation (SaO2) .90% at rest) without
musculoskeletal limitations were also submitted to incremental cardiopulmonary exercise testing (CPET).
RHC was performed using a Swan–Ganz catheter inserted percutaneously via the internal jugular vein.
Cardiac output was measured using the thermodilution technique. Pre-capillary PH was defined as mPAP
o25 mmHg and PAWP f15 mmHg at rest [2].
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Echocardiography was performed according to the American Society of Echocardiography guidelines [23]
using the modified Bernoulli equation and the right atrial pressure to estimate the systolic pulmonary
arterial pressure (sPAP).
Patients on continuous home oxygen therapy underwent RHC, the 6MWT and echocardiography under
their usual oxygen supplementation. RHC was performed 7–21 days after study enrolment and dyspnoea
quantification. All examinations were performed 1–14 days after RHC under stable clinical conditions.
Detailed methods are provided in the online supplementary material.
Statistical analysis
Data are presented as mean¡SD or median (interquartile range), unless otherwise stated. The distribution
of continuous variables was evaluated using Kolmogorov–Smirnov and Shapiro–Wilk tests. Comparisons
between patients with and without PH were made using a t-test or Mann–Whitney test, where appropriate.
Categorical variables were compared using Chi-squared and Fisher’s exact tests. Between-group
comparisons across different mPAP ranges were performed using ANOVA with Tukey’s post hoc analysis.
Correlations between variables were calculated using Pearson’s correlation coefficient. Receiver operating
characteristic (ROC) curves for forced vital capacity (FVC), diffusing capacity of the lung for carbon
monoxide (DLCO) and arterial oxygen tension (PaO2) at rest were derived while accounting for the presence
or absence of PH. The thresholds for each ROC curve were obtained from the points with the greatest sum
of sensitivity and specificity. Variables that were statistically significant in the univariate analysis (p,0.05)
were transformed into categorical variables based on the ROC analysis and included in a logistic regression
model to estimate the probability of PH. To avoid multicollinearity, only one of the highly correlated
1023 patients with ILD
95 with symptomatic chronic HP
69 eligible patients
25 had no PH
(mPAP <25 mmHg)
25 had PH
(mPAP ≥25 mmHg)
3 had post-capillary PH
(PAWP >15 mmHg)
22 had pre-capillary PH
(PAWP ≤15 mmHg)
50 underwent RHC
13 declined to undergo RHC
6 died before RHC
924 had other ILD diagnoses
2 with asymptomatic chronic HP
2 with chronic HP were >80 years old
26 were excluded:
  16 had left heart disease
  4 had obstructive sleep apnoea
  4 had connective tissue disease
  1 had congenital heart disease
  1 had schistosomiasis
FIGURE 1 Study flow diagram. ILD: interstitial lung disease; HP: hypersensitivity pneumonitis; RHC: right heart
catheterisation; PH: pulmonary hypertension; mPAP: mean pulmonary arterial pressure; PAWP: pulmonary arterial
wedge pressure.
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variables (ro0.6) was included in the model. p,0.05 was considered significant. The statistical analyses
were performed using SPSS software, version 19 (IBM Company, Armonk, NY, USA).
Results
Prevalence of PH and overall cohort description
A total of 95 consecutive symptomatic patients with chronic HP were evaluated. 26 were excluded because
of significant comorbidities, six died before RHC and 13 declined to participate. 50 patients underwent
RHC; 25 (50%) had PH and 22 (44%) demonstrated a pre-capillary pattern (fig. 1). Most patients had mild
PH, with mPAP f35 mmHg (fig. 2).
The main exposures were to moulds (n524), birds (n58) or both (n517), and one patient had hot-tub
lung. Lung biopsies were performed in 33 (66%) patients. Of these, 12 showed the classic histological triad,
16 showed bronchiolocentric interstitial pneumonia, three showed NSIP and two showed UIP-like findings.
The diagnosis of 17 (34%) patients was based on clinical and radiological findings. In total, 32 patients were
being treated with corticosteroids, with a median dose of 20 mg per day. The median disease duration from
diagnosis was 23 months, with an interquartile range of 3–71 months. All patients were nonsmokers or ex-
smokers and no patient had emphysema on HRCT. The patients’ baseline characteristics are shown
in table 1.
Comparisons of patients with and without pre-capillary PH at RHC
Patients with pre-capillary PH had significantly lower FVC, forced expiratory volume in the 1 s (FEV1),
DLCO, PaO2 and oxygen saturation values at the end of the 6MWT compared with patients without PH
(table 1). In contrast, the absence of anti-inflammatory therapy, the histological pattern and the disease
duration from diagnosis were not associated with PH (data not shown). Haemodynamic, pulmonary
function and echocardiographic characteristics across different mPAP ranges, as assessed by RHC, are
shown in table 2.
FVC and FEV1 values could not be obtained in two patients. DLCO values could not be obtained in nine
patients; in seven of these patients, this was because their FVC was ,1 L. Moreover, sPAP could not be
estimated for 17 patients (eight from the pre-capillary PH group) because of a lack of a detectable tricuspid
regurgitant jet.
There were significant inverse correlations between mPAP and PaO2 (r50.57, p,0.01), FVC (r50.44,
p,0.01) and DLCO (r50.37, p50.02). ROC analysis (fig. 3) demonstrated an area under the curve of 0.78
for PaO2 (95% CI 0.63–0.92, p,0.01), 0.73 for FVC (95% CI 0.57–0.89, p50.01) and 0.69 for DLCO (95% CI
0.52–0.86, p50.05). Based on the ROC analysis, an FVC of 60%, PaO2 of 70 mmHg and DLCO of 50% were
the optimal cut-offs in the presence of pre-capillary PH. In the multivariate analysis, these FVC (hazard
ratio (HR) 4.18, 95% CI 1.10–17.54; p50.04) and PaO2 (HR 7.04, 95% CI 1.66–30.30; p,0.01) cut-offs were
shown to be independent predictors of pre-capillary PH.
Cardiopulmonary exercise testing
In total, 33 nonhypoxaemic patients (SaO2.90%) were enrolled for CPET. Four patients could not undergo
CPET because of musculoskeletal limitations, so 29 patients were evaluated. These patients had less severe
ILD than did the patients who did not undergo CPET, as indicated by higher FVC (mean¡SD 65¡21%
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FIGURE 2 Patients’ frequency distribu-
tion across mean pulmonary arterial
pressure (mPAP) ranges. Patients with
a post-capillary haemodynamic pattern
had an mPAP of 25–35 mmHg (n52)
or .35 mmHg (n51).
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versus 50¡20% predicted, p50.03) and PaO2 (72.8¡7.5 versus 51.9¡10.6 mmHg, p,0.01) values. None of
the patients with mPAP .35 mmHg underwent CPET because of low SaO2 at rest. Oxygen uptake (V9O2) at
peak exercise and at the anaerobic threshold (AT) was significantly lower in the PH group (table 3).
However, no significant differences were found for the other CPET parameters. Among the 29 patients who
underwent CPET, the patients with pre-capillary PH (n510) had lower values than did the patients without
PH (n519) for FVC (55¡10% versus 70¡23% predicted, p50.02), DLCO (37¡10% versus 49¡15%
predicted, p50.03) and PaO2 (68.5¡5.8 versus 75.1¡7.5 mmHg, p50.02).
Echocardiography
Nearly all patients for whom echocardiography indicated sPAP o40 mmHg had pre-capillary PH, as
confirmed by RHC (fig. S1). However, patients with pre-capillary PH had the greatest differences between
the sPAP values estimated by echocardiography and values measured by RHC (fig. 4). In this patient
subgroup, echocardiography underestimated the value provided by invasive measurement by up to
23 mmHg and overestimated by up to 38 mmHg. In the group without PH, most patients presented a
difference of ¡10 mmHg between the two measurements.
PH risk assessment score
We found that at least two of the following findings were present in 76% of patients with chronic HP and
pre-capillary PH: FVC f60% predicted, PaO2 f70 mmHg and sPAP o40 mmHg on echocardiography.
There were no cases of PH among patients with none of these findings. Based on this observation, we
TABLE 1 Baseline characteristics of patients with symptomatic chronic hypersensitivity pneumonitis
Total Non-PH Pre-capillary PH p-value#
Patients 50 25 22
Females 39 (78) 21 (84) 15 (68) 0.18
Age years 61¡11 61¡12 60¡11 0.80
Body mass index kg?m-2 28¡5 28¡5 28¡6 0.59
Baseline dyspnoea index 6¡2 6¡2 5¡2 0.07
NYHA functional class II/III/IV 18/27/2 10/15/0 8/12/2 0.31
Pulmonary function testing"
FVC % predicted 59¡22 69¡22 50¡17 ,0.01
FEV1 % predicted 65¡24 75¡23 54¡17 ,0.01
DLCO % predicted 44¡15 47¡14 37¡12 0.03
FVC/DLCO % predicted 1.5 (1.4–1.7) 1.5 (1.3–1.7) 1.6 (1.4–1.8) 0.68
Blood gas analysis
PaO2 at rest mmHg 68.5 (54.5–75.0) 73.0 (62.2–78.5) 59.0 (47.8–69.3) ,0.01
PaCO2 at rest mmHg 37.9¡4.7 37.5¡3.8 38.1¡5.4 0.68
6-min walk test
Distance m 338¡105 365¡99 321¡108 0.15
Final SpO2 % 82¡9 86¡7 78¡8 ,0.01
Echocardiography+
TRV m?s-1 2.8¡0.6 2.6¡0.3 3.1¡0.8 0.08
sPAP mmHg 35 (30–40) 34 (30–36) 38 (29–49) 0.31
NT-proBNP pg?mL-1 78.7 (44.9–143.1) 78.7 (49.7–128.4) 68.8 (34.8–145.8) 0.71
Right heart catheterisation
RAP mmHg 8¡4 7¡3 7¡4 0.72
mPAP mmHg 25 (21–30) 21 (20–23) 30 (27–35) ,0.01
PAWP mmHg 10¡4 10¡3 10¡4 0.74
TPG mmHg 15 (11–19) 11 (10–14) 19 (17–25) ,0.01
PVR Wood units 3.2 (2.3–3.8) 2.3 (1.9–2.8) 4.0 (3.5–4.9) ,0.01
Cardiac index L?min-1?m-2 2.8 (2.4–3.0) 2.8 (2.4–3.2) 2.7 (2.4–2.9) 0.59
Data are presented as n, n (%), mean¡SD or median (interquartile range), unless otherwise stated. PH: pulmonary hypertension; NYHA: New York
Heart Association; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; DLCO: diffusing capacity of the lung for carbon monoxide; PaO2:
arterial oxygen tension; PaCO2: arterial carbon dioxide tension; SpO2: arterial oxygen saturation measured by pulse oximetry; TRV: tricuspid
regurgitant jet velocity; sPAP: systolic pulmonary arterial pressure; NT-proBNP: N-terminal pro-brain natriuretic peptide; RAP: right atrial
pressure; mPAP: mean pulmonary arterial pressure; PAWP: pulmonary arterial wedge pressure; TPG: transpulmonary gradient; PVR: pulmonary
vascular resistance. #: comparing pre-capillary PH patients with non-PH patients. ": FVC and FEV1 values could not be obtained in two patients (one
from each group); DLCO values could not be obtained in nine patients (six from the pre-capillary PH group). +: 17 patients had no detectable
tricuspid regurgitant jet (eight from the pre-capillary PH group).
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developed a risk assessment score for PH. One point was given for each of the following findings: sPAP
o40 mmHg on echocardiography, FVC f60% predicted and PaO2 f70 mmHg. The absence of a
detectable tricuspid regurgitant jet was assigned zero points. The distribution of patients with and without
PH according to risk assessment scores is shown in table 4.
Discussion
In this study, we found that pre-capillary PH is common in symptomatic patients with chronic HP, with a
prevalence of 44%, as assessed by RHC. Additionally, we found that pre-capillary PH is related to ILD
severity, as indicated by its greater frequency in hypoxaemic patients with reduced lung function and
exercise capacity.
Data on PH in chronic HP are scarce. Our study is the first to systematically evaluate PH using RHC in a
large cohort of patients with chronic HP. Two case-series studies have also been reported [15, 16]. LUPI-
HERRERA et al. [15] described 10 patients with invasively diagnosed HP whose mPAP was 22¡2 mmHg. All
of these patients were hypoxaemic. However, the study was conducted 2240 m above sea level, which raises
doubts about whether the PH and hypoxaemia were produced by ILD or high altitude [15]. In the second
study, COSTABEL et al. [16] reported nine cases of invasively studied HP, seven of which had mild PH (mPAP
20¡7 mmHg).
TABLE 2 Haemodynamic, pulmonary functional and echocardiographic characteristics across different mean pulmonary
arterial pressure (mPAP) ranges
mPAP
f20 mmHg
mPAP
21–24 mmHg
mPAP
25–35 mmHg
mPAP
.35 mmHg
p-value#
Patients n 7 18 17 5
PVR Wood units 2.2¡0.7 2.5¡0.5 4.2¡1.1*,1 6.0¡1.4*,1,e ,0.01
Cardiac index L?min-1?m-2 2.6¡0.5 2.9¡0.5 2.7¡0.3 2.7¡0.2 0.51
FVC" % predicted 65¡16 70¡24 52¡171 38¡141 0.01
PaO2 at rest mmHg 75.9¡8.3 68.8¡11.9 61.6¡11.2* 45.4¡9.4*
,1,e ,0.01
6MWT final SpO2 % 87¡6 85¡8 81¡7 69¡5*
,1,e ,0.01
TRV+ m?s-1 2.5¡0.3 2.7¡0.3 2.7¡0.5 3.8¡0.8*,1,e ,0.01
sPAP on echocardiography+ mmHg 33¡3 33¡6 34¡11 38¡16*,1,e ,0.01
Data are presented as mean¡SD unless otherwise stated. PVR: pulmonary vascular resistance; FVC: forced vital capacity; PaO2: arterial oxygen
tension; 6MWT: 6-min walk test; SpO2: arterial oxygen saturation measured by pulse oximetry; TRV: tricuspid regurgitant jet velocity; sPAP: systolic
pulmonary arterial pressure. #: intergroup comparison by ANOVA; ": could not be obtained in two patients (one had an mPAP of 21–24 mmHg and
one had mPAP .35 mmHg); +: 17 patients had no detectable tricuspid regurgitant jet (three had mPAP f20 mmHg, six had an mPAP of
21–24 mmHg, seven had an mPAP of 25–35 mmHg and one had mPAP .35 mmHg). *: p,0.05 compared with mPAP f20 mmHg; 1: p,0.05
compared with an mPAP of 21–24 mmHg; e: p,0.05 compared with an mPAP of 25–35 mmHg.
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One recent retrospective study based on echocardiographic diagnosis (sPAP o50 mmHg) described 73
patients with chronic HP with a 19% prevalence of PH [17], which is well below our finding of 44%. The
noninvasive diagnostic approach and retrospective design of the prior study may explain the lower
prevalence of PH compared with our results. Despite this difference in the reported prevalence of PH,
KOSCHEL et al. [17] found that PaO2 and FVC correlated with PH, although only PaO2 was significantly
decreased among patients with sPAP o50 mmHg.
Echocardiography is known to have certain limitations in PH diagnosis [8, 9], especially in parenchymal
lung diseases [10, 11]. If our study were based on only echocardiographic findings, we would have missed
TABLE 3 Cardiopulmonary exercise testing in nonhypoxaemic patients with symptomatic chronic hypersensitivity pneumonitis#
Non-PH Pre-capillary PH p-value
Patients n 19 10
Peak WR W 49 (38–55) 45 (30–64) 0.70
Metabolic responses
Peak V9O2 % predicted 80¡13 68¡20 0.06
Peak V9O2 mL?kg
-1?min-1 15.0¡2.5 12.8¡1.6 0.02
V9O2 at AT
" % V9O2max predicted 50¡8 41¡11 0.04
DV9O2/DWR mL?min
-1?W-1 8.8¡1.6 9.9¡2.9 0.24
Cardiovascular responses
Peak heart rate beats?min-1 124¡22 121¡14 0.72
Peak heart rate % predicted 77¡15 76¡5 0.75
Dheart rate/DV9O2 beats?L
-1 69¡27 62¡24 0.27
Peak V9O2/heart rate % predicted 97 (85–117) 99 (62–110) 0.51
Peak SBP mmHg 170 (160–170) 155 (150–163) 0.05
Ventilatory responses
V9E/MVV 0.61 (0.51–0.92) 0.66 (0.60–0.86) 0.65
DV9E/DV9CO2 40¡5 42¡6 0.78
V9E/V9CO2 at AT
" 37¡7 38¡7 0.67
Peak PETCO2 mmHg 35¡4 36¡5 0.61
PETCO2 at AT
" mmHg 37¡4 38¡5 0.79
Peak SpO2 % 93 (86–95) 87 (84–90) 0.06
Subjective responses
Peak dyspnoea Borg score 5¡2 6¡2 0.51
Peak leg effort Borg score 6¡2 5¡3 0.31
Data are presented as median (interquartile range) or mean¡SD, unless otherwise stated. PH: pulmonary hypertension; WR: work rate; V9O2:
oxygen uptake; AT: anaerobic threshold; D: change in; SBP; systolic blood pressure; V9E: minute ventilation; MVV: maximal voluntary ventilation;
V9CO2: carbon dioxide production; PETCO2: end-tidal carbon dioxide tension; SpO2: arterial oxygen saturation measured by pulse oximetry.
#: n529;
": we were not able to determine the AT in eight patients (three from the pre-capillary PH group).
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17 (34%) patients because of the absence of tricuspid regurgitation and would have failed to diagnose three
cases of post-capillary PH. Additionally, if the selection criteria for RHC were based on a tricuspid
regurgitant jet velocity (TRV) o2.5 m?s-1, 26 patients would have been deprived of invasive haemodynamic
evaluation, including 11 patients with pre-capillary PH and two patients with post-capillary PH. Therefore,
reliance solely on a PH suspicion threshold o2.5 m?s-1 for TRV on echocardiography would have missed
50% of the patients with pre-capillary PH.
Among patients with ILD, PH has been more frequently studied in idiopathic pulmonary fibrosis (IPF) and
sarcoidosis [24]. The prevalence of PH among patients with IPF ranges from 8% to 84% [3, 25, 26], with
higher prevalence among patients in lung transplant programmes [26]. However, PH is also common
among nonhypoxaemic patients with mild-to-moderate functional impairment, with a nearly 15%
prevalence as assessed by RHC [5]. This finding suggests that PH may be related to remodelling of the
pulmonary vascular bed, independent of the severity of lung fibrosis or hypoxaemia [27]. In sarcoidosis, the
prevalence of PH ranges from 6% to 74% [4, 28, 29] and PH can occur even in the absence of ILD [30].
However, PH is more frequent in patients with advanced parenchymal fibrosis [31], in which the
predominant mechanisms of PH are hypoxaemia, parenchymal destruction and distortion of the lung
microcirculation [32].
In contrast to IPF and similar to advanced stages of sarcoidosis, our findings suggest that in chronic HP, PH
severity is proportional to ILD severity. PH was more frequent among patients with lower lung function
and hypoxaemia. The latter is a well-known cause of PH induction via pulmonary vasoconstriction
and remodelling.
Beyond disease severity, the inflammatory response related to chronic HP [14] could represent another
possible contributor to PH development. Inflammatory mechanisms play important roles in the
pathogenesis of pulmonary arterial hypertension [33] and are, for example, assumed to contribute to
altered pulmonary circulation in chronic obstructive pulmonary disease [34]. Recent studies suggest that
allergen-induced lung inflammation is accompanied by significant pulmonary vascular hyperresponsiveness
and pulmonary arterial muscularisation, which may contribute to vascular remodelling and PH
development [35, 36]. However, in our study, anti-inflammatory therapy was not associated with an
absence of PH.
PH has a significant impact on exercise capacity in patients with ILD [37]. CPET has already been shown to
be effective in identifying PH in patients with IPF because of the remarkable ventilatory inefficiency present
when these patients develop PH [38]. In our study, a dynamic exercise evaluation using CPET showed
reduced exercise capacity in pre-capillary PH patients, as demonstrated by lower V’O2 at peak exercise and at
the AT than in patients without PH. We did not find any other ventilatory or metabolic PH predictors.
Possible explanations for this finding include that few patients were enrolled for CPET (n529) and that
CPET was performed only in nonhypoxaemic patients, i.e. those with less severe ILD. Another possible
explanation for our CPET findings is the likely different pathophysiologies of PH in IPF and PH in chronic
HP. Patients with IPF who develop PH may have pulmonary vasculopathy independent of ILD severity,
which could justify the presence of ventilatory inefficiency on CPET.
TABLE 4 Distribution of symptomatic patients with chronic hypersensitivity pneumonitis with
and without pulmonary hypertension according to the risk assessment score for pulmonary
hypertension
Points# mPAP at right heart catheterisation Total
,25 mmHg o25 mmHg
0 11 0 11
1 9 8 17
o2 4 13 17
Total 24 21 45
Data are presented as n. Chi-squared 17.00, p,0.01 by Fisher’s exact test. mPAP: mean pulmonary arterial
pressure. #: one point was given for each of the following findings: systolic pulmonary arterial pressure
o40 mmHg on echocardiography, forced vital capacity f60% predicted and arterial oxygen tension
f70 mmHg at rest. The absence of a detectable tricuspid regurgitant jet by echocardiography was assigned
zero points. Forced vital capacity values could not be obtained in two patients.
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Although the patients who underwent CPET had less severe pulmonary function impairment, the patients
with pre-capillary PH (n510) had lower FVC and PaO2 values than did the patients without PH who also
underwent CPET (n519), which reinforces the observation that pre-capillary PH is related to the severity of
chronic HP.
To help to identify patients with chronic HP and pre-capillary PH, we developed a risk assessment score for
PH using variables routinely obtained in outpatient settings (FVC, PaO2 and sPAP on echocardiography).
We found that scores o2 points were suggestive of PH and a score of zero indicated the absence of PH. This
risk assessment score could help physicians to stratify patients to identify those who need invasive
investigation by RHC. However, this score was derived from a small population, so further validation is
needed in a larger population with chronic HP before clinical use.
The presence of PH represents a known marker for a poor prognosis in ILD [1]. In chronic HP, the
prognosis is associated with the presence of fibrosis (especially a UIP-like pattern) but is not correlated with
FVC [39, 40]. Another predictor of survival is oxygen desaturation during exercise [12]. Furthermore, PH
seems to represent an adverse prognostic marker in patients with chronic HP [17]. Although the present
study was not designed to evaluate survival, we intend to follow this patient cohort over an extended period
to evaluate the utility of the presence of PH as a predictor of survival.
This study had certain limitations. It was a single-centre study, with potential bias in the patient selection
process. Another potential limitation is that we evaluated only patients with HRCT-confirmed fibrosis. This
population could have more severe ILD, which could affect the prevalence of PH. However, patients with
chronic HP and fibrosis are of greater interest regarding PH development compared with acute/subacute
HP cases that have potentially reversible disease. Additionally, we did not quantify fibrosis using HRCT.
However, the PFT parameters are assumed to be physiological correlates of the extent of lung fibrosis and,
therefore, could be sufficient to determine ILD severity.
Another limitation of our study is the number of patients in whom DLCO values could not be obtained
(n59), seven because their FVC was ,1 L. This may have influenced the correlation between DLCO and
mPAP, as HP was more frequent in patients with reduced FVC.
We did not evaluate serum precipitins because this test is not available in our country and we did not
perform bronchoalveolar lavage in many patients. However, there are no standardised diagnostic criteria for
chronic HP that require these two examinations. HP diagnosis depends on a high level of clinical suspicion,
recognition of relevant antigen exposure preceding the onset of respiratory symptoms (which represents a
key component of HP diagnosis), and the association of clinical, radiological, laboratory and pathological
findings [14, 19], without another identifiable cause of ILD.
In conclusion, our study demonstrated that pre-capillary PH in symptomatic patients with chronic HP is
common. The presence of PH is related to ILD severity, as indicated by the observation that PH was more
prevalent in hypoxaemic patients with greater impairment in lung function and lower exercise capacity.
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